Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994944 | 1.00 | USP30 (0.44) | USP30USP2SMN1; SMN2RECQLSMARCA2 | |
| SCHEMBL3772890 | 1.00 | USP30 (0.44) | USP30USP2SMN1; SMN2RECQLSMARCA2 | |
| SCHEMBL2943987 | 0.81 | USP30 (0.43) | USP30USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL2954128 | 0.81 | USP30 (0.43) | USP30USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL780002 | 0.81 | USP30 (0.43) | USP30USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL23422324 | 0.80 | USP30 (0.47) | USP30USP2SMN1; SMN2SMARCA2SMARCA4 | |
| SCHEMBL14815454 | 0.80 | USP30 (0.47) | USP30USP2SMN1; SMN2SMARCA2SMARCA4 | |
| SCHEMBL31027198 | 0.80 | USP30 (0.47) | USP30USP2SMN1; SMN2SMARCA2SMARCA4 | |
| SCHEMBL1441275 | 0.79 | USP2 (0.48) | USP30USP2SMN1; SMN2RECQLPIK3CD | |
| SCHEMBL3774805 | 0.79 | PIK3CD (0.39) | SMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651891-B1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| EP-2651932-B1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648070-B2 | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648070-B2 | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2012080457-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080456-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, SULT2A1 | USP30 1444/4885USP2 2045/4885SMN1; SMN2 2516/4885 |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, CCR1 | USP30 1787/4885USP2 3017/4885SMN1; SMN2 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.